Compare Pfizer Inc (PFE) vs Ralph Lauren Corp (RL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Ralph Lauren Corp — how do they compare? Pfizer Inc trades at $24.91 (market cap $142.14B), while Ralph Lauren Corp trades at $387.44 (market cap $22.79B). The key difference: Pfizer Inc is far larger — about 6.2× Ralph Lauren Corp's market cap, and Pfizer Inc pays the higher dividend (6.9%). Which is the better fit depends on your goals.
| PFE | RL | |
|---|---|---|
Market Cap | $142.14B | $22.79B |
Volume | 29,869,932 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $28.56 | $414.25 |
52-Week Low | $23.29 | $283.34 |
Enterprise Value | $192.80B | $23.73B |
Dividend Yield | 6.9% | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.
Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.
Ralph Lauren (RL) trades at $382.93, up 0.65% today, with strong fundamentals including 11.6% net margin and 34.66% ROE. Recent earnings beats and a $1.00 dividend signal financial health, though technical indicators show bearish momentum near resistance at $383. Revenue growth to $7.08B in 2025 and a $445.71 analyst target suggest upside potential.
The stock offers growth through premium branding and digital expansion, but faces risks from consumer discretionary weakness and high valuation multiples. Analyst consensus is strongly bullish (66% buy ratings), yet technical pressure and macroeconomic sensitivity warrant caution for near-term entry points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →
